SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	96.36	16.27
Short-Term Investments	11.08	-
Cash & Short-Term Investments	107.44	16.27
Cash Growth	560.41%	-
Other Receivables	0.43	0.42
Receivables	0.43	0.42
Prepaid Expenses	0.9	0.72
Total Current Assets	108.77	17.41
Property, Plant & Equipment	3.89	5.46
Long-Term Deferred Charges	2.72	-
Other Long-Term Assets	0.49	0.45
Total Assets	115.87	23.32
Accounts Payable	2.7	1.98
Accrued Expenses	2.18	1.28
Current Portion of Leases	-	0.44
Other Current Liabilities	3.71	4.09
Total Current Liabilities	8.58	7.79
Long-Term Leases	1.58	3.46
Total Liabilities	10.17	11.25
Additional Paid-In Capital	5.89	4.39
Retained Earnings	-104.73	-64.86
Total Common Equity	-98.84	-60.47
Shareholders' Equity	105.7	12.07
Total Liabilities & Equity	115.87	23.32
Total Debt	1.58	3.9
Net Cash (Debt)	105.85	12.37
Net Cash Growth	755.66%	-
Net Cash Per Share	47.74	6.92
Filing Date Shares Outstanding	2.2	1.79
Total Common Shares Outstanding	2.2	1.79
Working Capital	100.18	9.62
Book Value Per Share	-44.85	-33.82
Tangible Book Value	-98.84	-60.47
Tangible Book Value Per Share	-44.85	-33.82

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q